Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Lung Cancer

  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 196 articles:
HTML format

Single Articles

    June 2024
  1. SWITLIK W, Wyzewski Z, Gregorczyk-Zboroch K, Gietler M, et al
    Deciphering the Role of miR-30a-5p and DLGAP1 Gene in Non-small Cell Lung Cancer.
    Anticancer Res. 2024;44:2445-2451.
    PubMed     Abstract available

  2. ANO S, Kikuchi N, Okauchi S, Numata T, et al
    Real Clinical Practice of Combined Atezolizumab Plus Chemotherapy in Patients With Small Cell Lung Cancer.
    Anticancer Res. 2024;44:2725-2730.
    PubMed     Abstract available

  3. ENDO K, Tanaka H, Matsuo H, Onoda T, et al
    Adverse Event Profile of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Combination Therapy Based on JADER.
    Anticancer Res. 2024;44:2653-2660.
    PubMed     Abstract available

  4. SEO HR, Kim HJ, Ryu H, Song JY, et al
    Ionizing Radiation-treated NRF2-deficient Cancer Cells Promote Type I Interferon Signaling in Immune Cells.
    Anticancer Res. 2024;44:2577-2585.
    PubMed     Abstract available

  5. PARK JS, Park HY, Choi Y
    Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission Tomography/Computed Tomography in Lung Cancer.
    Anticancer Res. 2024;44:2681-2687.
    PubMed     Abstract available

    May 2024
  6. SOLIS-ESTRADA J, Arredondo-Espinoza E, Pioquinto-Avila E, Gonzalez-Cruz AO, et al
    Design and Evaluation of a Humanized Anti-EGFR huscFv Antibody Fragment in Combination With Metformin in A549 Cells In Vitro.
    Anticancer Res. 2024;44:1955-1962.
    PubMed     Abstract available

  7. CHEN LH, Tsai YF, Wu WT, Chiu KL, et al
    Association of Matrix Metalloproteinase-9 Genotypes With Lung Cancer Risk in Taiwan.
    Anticancer Res. 2024;44:1845-1852.
    PubMed     Abstract available

  8. RADES D, Cremers F, Janssen S, Bartscht T, et al
    Associations Between Mean Lung Dose and Prevalence of Radiation Pneumonitis in Elderly Lung Cancer Patients.
    Anticancer Res. 2024;44:2073-2079.
    PubMed     Abstract available

  9. CHOI YJ, Chung YH, Lee K, Jeong M, et al
    SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring BRAF G469A Mutation by Inhibiting the MAPK Signaling Pathway.
    Anticancer Res. 2024;44:1905-1913.
    PubMed     Abstract available

  10. JI N, Lee Y, Lee SH, Kim HS, et al
    Diagnostic Value of Immunostaining for Thyroid Transcription Factor 1 (TTF1) and Paired Box 8 (PAX8) in Distinguishing Pulmonary Metastases of Mesonephric and Mesonephric-like Adenocarcinomas from Primary Lung Adenocarcinomas.
    Anticancer Res. 2024;44:2159-2170.
    PubMed     Abstract available

  11. CHARPIDOU A, Mani M, Kokkotou E, Stournara L, et al
    Molecular Diagnostics and Treatment Patterns in Metastatic Non-small Cell Lung Cancer Patients: Real World Evidence from Greece: LACHESIS Study.
    Anticancer Res. 2024;44:2063-2072.
    PubMed     Abstract available

  12. KOH YW, Han JH, Haam S, Lee HW, et al
    Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:2081-2089.
    PubMed     Abstract available

    April 2024
  13. MAEZAWA Y, Taguchi M, Kawakami T, Inui T, et al
    Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study.
    Anticancer Res. 2024;44:1751-1757.
    PubMed     Abstract available

  14. CHIU KL, Wang SC, Li CH, Shen TC, et al
    The Contribution of Double-strand Break Repair Radiation Sensitive Protein 51 Genotypes to Lung Cancer in Taiwan.
    Anticancer Res. 2024;44:1409-1416.
    PubMed     Abstract available

  15. HASHIMOTO K, Kaira K, Imai H, Miura YU, et al
    Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer.
    Anticancer Res. 2024;44:1541-1551.
    PubMed     Abstract available

    March 2024
  16. INOMATA M, Minatoyama S, Takata N, Hayashi K, et al
    Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy.
    Anticancer Res. 2024;44:1241-1245.
    PubMed     Abstract available

  17. KINOSHITA H, Kinoshita S, Kamoda H, Hagiwara Y, et al
    Combined Auranofin and Celecoxib Suppresses the Local Progression and Pulmonary Metastases of Osteosarcoma In Vivo.
    Anticancer Res. 2024;44:1045-1049.
    PubMed     Abstract available

  18. YOSHIDA C, Kadota K, Ibuki E, Ishikawa R, et al
    Siglec10 Expression on Tumor-associated Macrophages Is an Independent Prognostic Factor in Stage I Lung Adenocarcinoma.
    Anticancer Res. 2024;44:1289-1297.
    PubMed     Abstract available

    February 2024
  19. NATSUME K, Ye J, Mukai Y, Yamakawa K, et al
    Discrepancies Between Morphological and Immunohistochemical Classifications Are Associated With Prognoses and Subtypes of Lung Cancer.
    Anticancer Res. 2024;44:711-722.
    PubMed     Abstract available

  20. TRINH JQ, Xiong Y, Smith LM, Abughanimeh O, et al
    Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study.
    Anticancer Res. 2024;44:605-612.
    PubMed     Abstract available

  21. KANASAKI H, Ozawa Y, Nakamura N, Nagasaki K, et al
    Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2024;44:723-730.
    PubMed     Abstract available

  22. KURIHARA S, Nakamura R, Yoneyama S, Takase S, et al
    Prognostic Impact of Preoperative Assessment of Muscle Mass and Strength in Surgically Resected Lung Cancer.
    Anticancer Res. 2024;44:767-779.
    PubMed     Abstract available

  23. NAKAO M, Kinoshita R, Kuriyama M, Kiyotoshi H, et al
    Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer.
    Anticancer Res. 2024;44:845-851.
    PubMed     Abstract available

  24. CHECK JH, Check DL, DO TP, Srivastava M, et al
    Significant Palliative Benefits Following Therapy With Mifepristone for Advanced Treatment Resistant Small Cell Lung Cancer.
    Anticancer Res. 2024;44:659-664.
    PubMed     Abstract available

  25. MATSUMOTO T, Toya R, Shimohigashi Y, Yamaguchi K, et al
    Influence of Respiratory Motion on Dose Distribution in Gastric Mucosa-associated Lymphoid Tissue Lymphoma Radiotherapy.
    Anticancer Res. 2024;44:687-694.
    PubMed     Abstract available

  26. BARUT Z, Akdeniz FT, Isbir T
    Investigation of Mirna-223-3p Expression in Non-small Cell Lung Cancers.
    Anticancer Res. 2024;44:585-591.
    PubMed     Abstract available

  27. HONG JM, Jeong BK, Han D, Kim K, et al
    CCR10-mediated Enhancement of T Cell Trafficking for Improved Tumor Immunotherapy.
    Anticancer Res. 2024;44:521-532.
    PubMed     Abstract available

    January 2024
  28. NIEDER C, Aanes SG, Dalhaug A, Haukland EC, et al
    Sex Differences in Presentation, Treatment, and Survival in Patients Receiving Palliative (Chemo)Radiotherapy for Non-Small Cell Lung Cancer.
    Anticancer Res. 2024;44:301-305.
    PubMed     Abstract available

  29. CHEN PM, Huang YH, Chen HH, Chu PY, et al
    Catalase Expression Is an Independent Prognostic Marker in Lung Adenocarcinoma.
    Anticancer Res. 2024;44:287-300.
    PubMed     Abstract available

  30. TATE MK, Hernandez M, Chang JY, Lin SH, et al
    Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial.
    Anticancer Res. 2024;44:133-137.
    PubMed     Abstract available

  31. MOSER SS, Apter L, Solomon J, Chodick G, et al
    Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data.
    Anticancer Res. 2024;44:257-265.
    PubMed     Abstract available

    December 2023
  32. AGOLLI L, Eroglu Z, Nicosia L, Habermehl D, et al
    Dosimetric Parameters After VMAT Adaptive Radiotherapy in Patients With Locally Advanced NSCLC Undergoing 4DCT.
    Anticancer Res. 2023;43:5573-5582.
    PubMed     Abstract available

  33. LEE HH, Hsieh CC, Chang CC, Liao WT, et al
    YTHDF3 Modulates EGFR/ATK/ERK/p21 Signaling Axis to Promote Cancer Progression and Osimertinib Resistance of Glioblastoma Cells.
    Anticancer Res. 2023;43:5485-5498.
    PubMed     Abstract available

  34. KIMURA N, Kadota K, Ibuki E, Ishikawa R, et al
    (Pro)renin Receptor Down-regulation Is Associated With a Higher Risk of Recurrence in Lung Adenocarcinoma.
    Anticancer Res. 2023;43:5671-5680.
    PubMed     Abstract available

  35. TONG X, Zhang R, Sun R, Yang W, et al
    Disclosing Potential Therapeutic Targets Associated With Osimertinib Resistance in the Non-small Cell Lung Cancer Cell Line H1975.
    Anticancer Res. 2023;43:5459-5474.
    PubMed     Abstract available

  36. ENDO I, Amatya VJ, Kushitani K, Nakagiri T, et al
    Long Non-coding RNA LINC00152 Requires EZH2 to Promote Mesothelioma Cell Proliferation, Migration, and Invasion.
    Anticancer Res. 2023;43:5367-5376.
    PubMed     Abstract available

  37. LIU B, Pu ZY, Wang L, Fang J, et al
    Inhibiting miR-33b-5p Enhances Chemoresistance in Lung Adenocarcinoma by Targeting YWHAH to Regulate Epithelial-mesenchymal Transition.
    Anticancer Res. 2023;43:5447-5458.
    PubMed     Abstract available

  38. LIN HW, Shih TW, Amanna A, Chang MS, et al
    PHRF1 Promotes Cell Invasion by Modulating SOX4 Expression in Colorectal Cancer HCT116-p53(-/-) Cells.
    Anticancer Res. 2023;43:5437-5446.
    PubMed     Abstract available

  39. ZHANG XW, Mohr J, Halama N, Koschny R, et al
    Analysis of an Unselected Patient Cohort With Advanced Colorectal Carcinoma from a Maximum Care Center.
    Anticancer Res. 2023;43:5589-5596.
    PubMed     Abstract available

    November 2023
  40. ITO S, Tsurumi K, Shindo N, Soma S, et al
    Multi-gene Liquid Biopsy to Detect Resistance to First-line Osimertinib in Patients With EGFR-mutated Lung Adenocarcinoma.
    Anticancer Res. 2023;43:5031-5040.
    PubMed     Abstract available

  41. SAKAI K, Kuramoto J, Takahashi T, Kawano Y, et al
    Impact of Locoregional Therapies for Brain Lesions on Survival in Patients With Non-small Cell Lung Cancer With Multiple Extrathoracic Metastases.
    Anticancer Res. 2023;43:5107-5114.
    PubMed     Abstract available

  42. ITO A, Tarukawa T, Suzuki Y, Sakaguchi T, et al
    Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:5197-5204.
    PubMed     Abstract available

  43. YANG T, Si Q, Liu M, DU R, et al
    Novel Biomarker miRNA-625-3p Promotes Cell Proliferation and Metastasis of Lung Adenocarcinoma by Targeting KLF9.
    Anticancer Res. 2023;43:4923-4935.
    PubMed     Abstract available

  44. MATSUDO K, Takenaka T, Hashinokuchi A, Nagano T, et al
    Impact of Chronic Obstructive Pulmonary Disease on the Long-term Prognosis of Patients Undergoing Lobectomy for Non-small-cell Lung Cancer: A Propensity Score-matched Analysis.
    Anticancer Res. 2023;43:5215-5222.
    PubMed     Abstract available

  45. ISOYAMA-SHIRAKAWA Y, Yoshitake T, Ninomiya K, Asai K, et al
    Combination of Clinical Factors and Radiomics Can Predict Local Recurrence and Metastasis After Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer.
    Anticancer Res. 2023;43:5003-5013.
    PubMed     Abstract available

    October 2023
  46. TAMURA T, Numata T, Yanai H, Nakamura R, et al
    Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI).
    Anticancer Res. 2023;43:4583-4591.
    PubMed     Abstract available

  47. SAWABATA N, Morita K, Tatsumi S, Fujii T, et al
    A Novel Filtration Membrane for Clustered Circulating Tumor Cell Extraction: A Prospective Feasibility Study.
    Anticancer Res. 2023;43:4683-4690.
    PubMed     Abstract available

  48. NAGAMINE H, Yashiro M, Yoshimoto N, Izumi M, et al
    RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression.
    Anticancer Res. 2023;43:4663-4672.
    PubMed     Abstract available

  49. ZHAO QI, Ren W, Gao S, Mu N, et al
    Immune Cell Infiltration and Clinical Significance of Angiogenesis-related Genes in Lung Adenocarcinoma.
    Anticancer Res. 2023;43:4473-4489.
    PubMed     Abstract available

    September 2023
  50. ENDO I, Amatya VJ, Kushitani K, Kambara T, et al
    FOXM1 Promotes Mesothelioma Cell Migration and Invasion via Activation of SMAD Signaling.
    Anticancer Res. 2023;43:3961-3968.
    PubMed     Abstract available

  51. SAIJO H, Hirohashi Y, Honjo O, Saikai T, et al
    Anti-CTLA-4 Antibody Might Be Effective Against Non-small Cell Lung Cancer With Large Size Tumor.
    Anticancer Res. 2023;43:4155-4160.
    PubMed     Abstract available

  52. ROSENBROCK J, Lieser A, Ostermann-Myrau J, Judge M, et al
    Efficacy and Toxicity of Robotic Stereotactic Body Radiotherapy of Lung Metastases in Patients With Oligometastatic Disease.
    Anticancer Res. 2023;43:4125-4131.
    PubMed     Abstract available

    August 2023
  53. MIYAHARA N, Hiratsuka M, Okamoto Y, Teishikata T, et al
    Is the Preoperative Prognostic Nutritional Index a Useful Marker for the Decision to Perform Limited Resection in High-risk Patients With Stage I Non-small Cell Lung Cancer?
    Anticancer Res. 2023;43:3659-3664.
    PubMed     Abstract available

  54. LEE YH, Wang SC, Li CH, Chen LH, et al
    The Contribution of DNA Ligase 4 Genetic Variations to Taiwanese Lung Cancer.
    Anticancer Res. 2023;43:3447-3453.
    PubMed     Abstract available

  55. OKAMOTO T, Takenaka T, Yamazaki K, Hamatake M, et al
    Prognostic Impact of Central Nervous System Recurrence After Surgery in Patients With Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer.
    Anticancer Res. 2023;43:3543-3551.
    PubMed     Abstract available

  56. HUNT A, Haque W, Pino R, Farach A, et al
    Radiation Pneumonitis, Really? A Case of Pulmonary Toxicity from CDK4/6 Inhibitor.
    Anticancer Res. 2023;43:3539-3542.
    PubMed     Abstract available

    July 2023
  57. TAN CQY, Ho A, Robinson HA, Huang L, et al
    A Systematic Review of Microwave Ablation for Colorectal Pulmonary Metastases.
    Anticancer Res. 2023;43:2899-2907.
    PubMed     Abstract available

  58. INOMATA M, Matsumoto M, Hayashi K, Seto Z, et al
    Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.
    Anticancer Res. 2023;43:3241-3246.
    PubMed     Abstract available

  59. KARTALOGLU EB, Oztepe M, Akgun O, Acun T, et al
    Identification of ALX3 Gene Promoter Hypermethylation as a Potential Biomarker for Lung Cancer.
    Anticancer Res. 2023;43:3029-3036.
    PubMed     Abstract available

  60. AOKI M, Kamimura GO, Morizono S, Tokunaga T, et al
    Clinical Significance of Nodal DCsign Expression in Non-small-cell Lung Cancer Patients.
    Anticancer Res. 2023;43:3003-3013.
    PubMed     Abstract available

  61. SASAKI T, Nakamura Y, Hata S, Shimada H, et al
    The GR-SGK1-NDRG1 Pathway as a Predictor of Recurrence and Prognosis in Lung Adenocarcinoma After Radical Surgery.
    Anticancer Res. 2023;43:2965-2974.
    PubMed     Abstract available

  62. CHEN SK, Lee W, Li YC, Hsu FT, et al
    Imipramine Induces Apoptosis and Inhibits the Metastatic Potential of Triple-negative Breast Cancer Cells.
    Anticancer Res. 2023;43:2985-2994.
    PubMed     Abstract available

  63. ZHAO L, Kaser E, Lequio M, D'Mello K, et al
    Say 'No' to Cancer and 'Yes' to Cranberry: The Role of Cranberry Extract in Inhibition of Growth of Lung Adenocarcinoma Cells.
    Anticancer Res. 2023;43:2933-2939.
    PubMed     Abstract available

  64. SUZUKI H, Sasaki E, Tamaki T, Kodaira T, et al
    Association Between 18F-Fluorodeoxyglucose Uptake and Mutation Status of Epidermal Growth Factor Receptor in Sinonasal Tract Cancer.
    Anticancer Res. 2023;43:3247-3253.
    PubMed     Abstract available

    June 2023
  65. KANAOKA K, Tamiya A, Inagaki Y, Taniguchi Y, et al
    Possible False Results With cobas((R)) EGFR Mutation Test v2 and Oncomine Dx Target Test for EGFR Mutation.
    Anticancer Res. 2023;43:2771-2776.
    PubMed     Abstract available

  66. LINARDOU H, Lampaki S, Koliou GA, Vozikis A, et al
    Real-world Data and Economic Evaluation of Nivolumab in Previously Treated Non-small Cell Lung Cancer Greek Patients.
    Anticancer Res. 2023;43:2799-2812.
    PubMed     Abstract available

    May 2023
  67. NAKAHAMA K, Izumi M, Yoshimoto N, Fukui M, et al
    Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data.
    Anticancer Res. 2023;43:2185-2197.
    PubMed     Abstract available

  68. KIM H, Lim DH, Kwon YS, Kim MA, et al
    Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Anticancer Res. 2023;43:2343-2349.
    PubMed     Abstract available

  69. NAKAMURA M, Ishikawa H, Ohnishi K, Baba K, et al
    Long-term Outcomes After Moderate Hypofractionated Proton Therapy for Centrally Located Non-small Cell Lung Cancer.
    Anticancer Res. 2023;43:2003-2013.
    PubMed     Abstract available

  70. MOUNTZIOS G, Koumarianou A, Linardou H, Boutis A, et al
    Clinical Outcomes Beyond 1L EGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study 'LUNGFUL'.
    Anticancer Res. 2023;43:2243-2258.
    PubMed     Abstract available

  71. RADES D, Al-Salool A, Bohnet S, Yu NY, et al
    Prevalence of and Risk Factors for Emotional Distress in Patients Undergoing Radiotherapy for Lung Cancer.
    Anticancer Res. 2023;43:2111-2118.
    PubMed     Abstract available

  72. KERROUCH H, Danset M, Hjira N, Kanitakis J, et al
    Metastatic Adenocarcinoma of the Lung Presenting as a Presternal Cutaneous Mass: Case Report and Brief Literature Review.
    Anticancer Res. 2023;43:2367-2370.
    PubMed     Abstract available

    April 2023
  73. JEONG WG, Kim YH, Ahn SJ, Jeong JU, et al
    Effect of Interstitial Lung Abnormality on Concurrent Chemoradiotherapy-treated Stage III Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2023;43:1797-1807.
    PubMed     Abstract available

  74. TANDA M, Yamamoto K, Hori T, Nishiguchi H, et al
    Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients.
    Anticancer Res. 2023;43:1775-1783.
    PubMed     Abstract available

  75. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Surgical Outcomes After Pulmonary Resection With Typical or Atypical Bronchoplasty in Patients With Primary Lung Cancer.
    Anticancer Res. 2023;43:1719-1724.
    PubMed     Abstract available

  76. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Elevation of the Neutrophil-to-Lymphocyte Ratio Is a Significant Postoperative Poor Prognostic Factor in Patients With Clinical T3-4 Centrally Located Primary Lung Cancer.
    Anticancer Res. 2023;43:1631-1636.
    PubMed     Abstract available

  77. MIYOSHI AI, Ueda Y, Kurita T, Kimura T, et al
    Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix.
    Anticancer Res. 2023;43:1397-1405.
    PubMed     Abstract available

    March 2023
  78. MUSA MA, Kolawole Q
    7,8-Diacetoxy-3-(4-methylsulfonylphenyl)-4-phenylcoumarin Induces ROS-dependent Cell Death in the A549 Human Lung Cancer Cell Line.
    Anticancer Res. 2023;43:1001-1007.
    PubMed     Abstract available

  79. TAMIYA A, Tamiya M, Inagaki Y, Taniguchi Y, et al
    Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting.
    Anticancer Res. 2023;43:1325-1330.
    PubMed     Abstract available

  80. CHECK JH, Poretta T, Check D, Srivastava M, et al
    Lung Cancer - Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators.
    Anticancer Res. 2023;43:951-965.
    PubMed     Abstract available

  81. FANG XQ, Lee S, Kim YS, Han GE, et al
    Streptonigrin Mitigates Lung Cancer-induced Cachexia by Suppressing TCF4/TWIST1-induced PTHLH Expression.
    Anticancer Res. 2023;43:1149-1157.
    PubMed     Abstract available

    February 2023
  82. YAMADA S, Sekine A, Hagiwara E, Onodera Y, et al
    Cumulative Incidence of Thromboembolism and Prognostic Impact of Stroke in BRAF V600E-mutant Non-small-cell Lung Cancer.
    Anticancer Res. 2023;43:935-938.
    PubMed     Abstract available

  83. IKEUCHI N, Igata F, Kinoshita E, Kawabata T, et al
    Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2023;43:713-724.
    PubMed     Abstract available

  84. ABE T, Iino M, Saito S, Aoshika T, et al
    Comparison of the Efficacy and Toxicity of Concurrent Chemoradiotherapy and Durvalumab and Concurrent Chemoradiotherapy Alone for Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Metastasis.
    Anticancer Res. 2023;43:675-682.
    PubMed     Abstract available

  85. YAMAZAKI M, Komizo N, Iihara H, Hirose C, et al
    Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer.
    Anticancer Res. 2023;43:725-732.
    PubMed     Abstract available

    January 2023
  86. AKINO Y, Shiomi H, Higashinaka N, Kouno T, et al
    Evaluation of Lung and Liver Tumor Dose Coverage Treated With the CyberKnife Synchrony System With Consideration of Measured Tracking Errors.
    Anticancer Res. 2023;43:231-238.
    PubMed     Abstract available

    December 2022
  87. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Detailed Surgical Techniques and Short-term Clinical Outcomes of Sleeve Lobectomy for Locally Advanced Right Lower Lobe Lung Cancer.
    Anticancer Res. 2022;42:5977-5982.
    PubMed     Abstract available

  88. LIM CH, Koh YW, Hyun SH, Lee SJ, et al
    A Machine Learning Approach Using PET/CT-based Radiomics for Prediction of PD-L1 Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:5875-5884.
    PubMed     Abstract available

  89. KASHIWABARA K, Fujii S, Tsumura S, Sakamoto K, et al
    Overall Survival of Small-cell Lung Cancer Patients With Malignant Central Airway Obstruction Who Received Chemotherapy Without Undergoing Transbronchial Interventions: A Single-institution Retrospective Study.
    Anticancer Res. 2022;42:6113-6119.
    PubMed     Abstract available

  90. PARTYNSKA A, Piotrowska A, Pawelczyk K, Rzechonek A, et al
    The Expression of Histone Acetyltransferase KAT6A in Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:5731-5741.
    PubMed     Abstract available

  91. SHIMOMURA K, Yamaguchi T, Oya Y, Uchida K, et al
    Impact of Corticosteroids for IrAEs on the Clinical Outcome of Immunotherapy in Patients With NSCLC.
    Anticancer Res. 2022;42:5961-5969.
    PubMed     Abstract available

    November 2022
  92. SATO K, Nakamura S, Kadomatsu Y, Ueno H, et al
    Neoadjuvant Therapy for Patients With Non-small Cell Lung Cancer Complicated With Chest Wall Invasion.
    Anticancer Res. 2022;42:5539-5546.
    PubMed     Abstract available

    October 2022
  93. DAMEN PJJ, Suijkerbuijk KPM, VAN Lindert ASR, Eppinga WSC, et al
    Long-term Local Control and Overall Survival After Radiotherapy in Oligoprogressive Patients During Treatment With Checkpoint Inhibitors.
    Anticancer Res. 2022;42:4795-4804.
    PubMed     Abstract available

  94. TAKAYAMA Y, Yano J, Seike R, Mishima S, et al
    Efficacy of Chemoimmunotherapy in NSCLC Patients With Brain Metastasis With or Without Prior Brain Radiotherapy.
    Anticancer Res. 2022;42:4805-4812.
    PubMed     Abstract available

  95. MATSUI Y, Yamada T, Morimoto K, Katayama Y, et al
    Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer.
    Anticancer Res. 2022;42:4921-4928.
    PubMed     Abstract available

    September 2022
  96. HATTORI S, Okauchi S, Sasatani Y, Ohara G, et al
    Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation.
    Anticancer Res. 2022;42:4589-4595.
    PubMed     Abstract available

  97. STOLERIU MG, Stathopoulos G, Stacher-Priehse E, Ketscher C, et al
    Predicting Long-term Survival After Lung Metastasectomy in Patients With Malignant Germ-cell Tumors.
    Anticancer Res. 2022;42:4517-4527.
    PubMed     Abstract available

  98. SUKPRASANSAP M, Chanvorachote P
    Evidence of Potential Plant-derived Compounds With Anticancer Effects on Lung Cancer: Clinical and Molecular Pharmacology Approaches.
    Anticancer Res. 2022;42:4247-4258.
    PubMed     Abstract available

  99. MORITA K, Sawabata N, Tatsumi S, Fujii T, et al
    Verification of A New Filter for Isolation of Circulating Tumor Cells by Only Blood Filtration.
    Anticancer Res. 2022;42:4305-4310.
    PubMed     Abstract available

  100. TAN C, Fisher OM, Huang L, Alzahrani N, et al
    Comparison of Microwave and Radiofrequency Ablation in the Treatment of Pulmonary Metastasis of Colorectal Cancer.
    Anticancer Res. 2022;42:4563-4571.
    PubMed     Abstract available

  101. CHANVORACHOTE P, Petsri K, Thongsom S
    Epithelial to Mesenchymal Transition in Lung Cancer: Potential EMT-Targeting Natural Product-derived Compounds.
    Anticancer Res. 2022;42:4237-4246.
    PubMed     Abstract available

    August 2022
  102. JANPIPATKUL K, Panvongsa W, Worakitchanon W, Reungwetwattana T, et al
    Extracellular Vesicles from EGFR T790M/L858R-mutant Non-small Cell Lung Cancer Promote Cancer Progression.
    Anticancer Res. 2022;42:3835-3844.
    PubMed     Abstract available

  103. LEE YC, Weng YS, Wang HY, Hsu FT, et al
    Magnolol Induces Apoptosis Through Extrinsic/intrinsic Pathways and Attenuates NF-kappaB/STAT3 Signaling in Non-small-cell Lung Cancer Cells.
    Anticancer Res. 2022;42:3825-3833.
    PubMed     Abstract available

    July 2022
  104. RAJHA A, Piso P, Halmy L, Panczel I, et al
    Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Anticancer Res. 2022;42:3681-3692.
    PubMed     Abstract available

  105. SATO J, Nakano K, Shimizu T, Uchida M, et al
    Evaluation of Durvalumab-induced Lung Toxicity Using a Spontaneous Reporting Database.
    Anticancer Res. 2022;42:3575-3582.
    PubMed     Abstract available

  106. KIM YJ, Hong SE, Jang SK, Park KS, et al
    Knockdown of NUPR1 Enhances the Sensitivity of Non-small-cell Lung Cancer Cells to Metformin by AKT Inhibition.
    Anticancer Res. 2022;42:3475-3481.
    PubMed     Abstract available

  107. WU MF, Chen LH, Hsia NY, Shen YC, et al
    Significant Contribution of Interleukin-18 Genotypes to Lung Cancer Risk in Taiwanese.
    Anticancer Res. 2022;42:3381-3387.
    PubMed     Abstract available

  108. NAKANO T, Yasumatsu R, Hashimoto K, Kuga R, et al
    Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study.
    Anticancer Res. 2022;42:3653-3664.
    PubMed     Abstract available

  109. SHAM NO, Zhao L, Zhu Z, Roy TM, et al
    Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets.
    Anticancer Res. 2022;42:3275-3284.
    PubMed     Abstract available

    June 2022
  110. NAKAMURA R, Yoneyama S, Tobita R, Kurihara S, et al
    Effect of Postoperative Muscle Loss After Resection of Non-small Cell Lung Cancer on Surgical Outcomes.
    Anticancer Res. 2022;42:3159-3168.
    PubMed     Abstract available

  111. MATSUMURA K, Yamamura K, Oda E, Akahoshi S, et al
    Successful Treatment of Intrahepatic Cholangiocarcinoma With Liver/Lung Metastasis and Peritoneal Dissemination After Liver Resection.
    Anticancer Res. 2022;42:3209-3215.
    PubMed     Abstract available

  112. SATO J, Uchida M, Wakabayashi H, Shimizu T, et al
    Evaluation of Lung Toxicity Related to the Treatment With Alectinib Using a Pharmacovigilance Database.
    Anticancer Res. 2022;42:3109-3116.
    PubMed     Abstract available

  113. SHAMAVONIAN R, Cheng E, Karpes JB, Barat S, et al
    Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre.
    Anticancer Res. 2022;42:2939-2944.
    PubMed     Abstract available

  114. HIROSHIMA Y, Tamaki Y, Sawada T, Ishida T, et al
    Stereotactic Body Radiotherapy for Stage I Lung Cancer With a New Real-time Tumor Tracking System.
    Anticancer Res. 2022;42:2989-2995.
    PubMed     Abstract available

  115. BOLLER D, Doepfner KT, Laurentiis A, Guerreiro AS, et al
    Republication: Targeting PI3KC2beta Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours.
    Anticancer Res. 2022;42:3217-3230.
    PubMed     Abstract available

  116. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Large Tumor Size and High Neutrophil-to-lymphocyte Ratio Predicts Poor Prognosis After Pneumonectomy or Sleeve Lobectomy in Patients With Non-small-cell Lung Cancer.
    Anticancer Res. 2022;42:3029-3034.
    PubMed     Abstract available

  117. TU CY, Chen HJ, Hsia TC, Fang HY, et al
    Adjuvant Concurrent Chemoradiotherapy Versus Adjuvant Chemotherapy Only in Locally Advanced Non-small-cell Lung Cancer With Involved Microscopic Resection Margin: A Population-based Cohort Study.
    Anticancer Res. 2022;42:3195-3201.
    PubMed     Abstract available

  118. KASHIWAGI K, Sato-Yazawa H, Ishii J, Kohno K, et al
    LXRbeta Activation Inhibits the Proliferation of Small-cell Lung Cancer Cells by Depleting Cellular Cholesterol.
    Anticancer Res. 2022;42:2923-2930.
    PubMed     Abstract available

  119. NAKAMURA M, Ishikawa H, Ohnishi K, Baba K, et al
    Proton Beam Therapy in Elderly Patients With cT1-3N0M0 Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:2953-2960.
    PubMed     Abstract available

  120. NIEDER C, Aanes SG, Haukland EC
    Survival and Early Death Within Three Months from the Start of Immune Checkpoint Inhibitors in Patients With Different Types of Cancer.
    Anticancer Res. 2022;42:3061-3066.
    PubMed     Abstract available

    May 2022
  121. SHIOZAWA T, Numata T, Tamura T, Endo T, et al
    Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:2583-2590.
    PubMed     Abstract available

  122. WATANABE S, Yamazaki H, Kimoto T, Suzuki G, et al
    Repeated Stereotactic Body Radiotherapy for Lung Malignancies: Toxicity Can Be Reduced by Sparing Lung Irradiation.
    Anticancer Res. 2022;42:2701-2709.
    PubMed     Abstract available

  123. BASSANELLI M, Ramella S, Zeuli M, Ceribelli A, et al
    Radiotherapy and Immunotherapy: The Power of the Teamwork for the Treatment of NSCLC.
    Anticancer Res. 2022;42:2241-2247.
    PubMed     Abstract available

    April 2022
  124. CHEN CH, Chang JW, Chang CF, Huang CY, et al
    Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations.
    Anticancer Res. 2022;42:2145-2157.
    PubMed     Abstract available

  125. GLATZEL E, Werner EM, Bohnet S, Rades D, et al
    A Prognostic Tool to Estimate the Risk of Pneumonitis in Patients Irradiated for Lung Cancer.
    Anticancer Res. 2022;42:2029-2032.
    PubMed     Abstract available

  126. SVATON M, Bratova M, Koubkova L, Fischer O, et al
    Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?
    Anticancer Res. 2022;42:1987-1995.
    PubMed     Abstract available

  127. RADES D, Glatzel E, Bohnet S, Schild SE, et al
    Estimating the Probability of Not Completing the Intended Course of Thoracic Radiotherapy for Lung Cancer.
    Anticancer Res. 2022;42:1973-1977.
    PubMed     Abstract available

    March 2022
  128. KIM MH, Choi CM, Lee SY, Park CK, et al
    First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Anticancer Res. 2022;42:1615-1622.
    PubMed     Abstract available

  129. SVATON M, Drosslerova M, Fischer O, Marel M, et al
    Laboratory Parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:1563-1569.
    PubMed     Abstract available

  130. LI CH, Yang YC, Hsia TC, Shen TC, et al
    Association of Interleukin-8 Promoter Genotypes With Taiwan Lung Cancer Risk.
    Anticancer Res. 2022;42:1229-1236.
    PubMed     Abstract available

  131. II H, Kasahara Y, Yamaguma H, Kageyama S, et al
    Administration of Gapmer-type Antisense Oligonucleotides Targeting gamma-Glutamylcyclotransferase Suppresses the Growth of A549 Lung Cancer Xenografts.
    Anticancer Res. 2022;42:1221-1227.
    PubMed     Abstract available

  132. OTOSHI T, Nagano T, Park J, Hosomi K, et al
    The Gut Microbiome as a Biomarker of Cancer Progression Among Female Never-smokers With Lung Adenocarcinoma.
    Anticancer Res. 2022;42:1589-1598.
    PubMed     Abstract available

  133. YUMURA M, Nagano T, Jimbo N, Dokuni R, et al
    Annexin A10 Expression as a Novel Prognostic Marker in Lung Adenocarcinoma.
    Anticancer Res. 2022;42:1289-1294.
    PubMed     Abstract available

    February 2022
  134. JOGIAT UM, Chu QS, Nagendran J, Laing B, et al
    Bilateral Lung Transplant for Treatment of Idiopathic Pulmonary Fibrosis With Undetected Lung Adenocarcinoma: A Case Report.
    Anticancer Res. 2022;42:1157-1160.
    PubMed     Abstract available

  135. TAKENAKA T, Tagawa T, Kohno M, Haratake N, et al
    Consideration of the Optimal Surgical Procedure Based on the Risk of Recurrence in Clinical Stage 0 or IA Lung Adenocarcinoma.
    Anticancer Res. 2022;42:1137-1142.
    PubMed     Abstract available

  136. HORIUCHI M, Oguri T, Kagawa Y, Sone K, et al
    Differences in the Therapeutic Effect of Chemotherapy Regimens for Concurrent Chemoradiotherapy of Locally Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2022;42:1073-1079.
    PubMed     Abstract available

  137. TAKANO N, Seike M, Sugano T, Matsuda K, et al
    A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed.
    Anticancer Res. 2022;42:709-722.
    PubMed     Abstract available

    January 2022
  138. MESSEHA SS, Nezami MA, Hager S, Soliman KFA, et al
    A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer Harboring EGFR L747P Mutation With Clinical Response to Multi-targeted Epigenetic and EGFR Inhibition.
    Anticancer Res. 2022;42:441-447.
    PubMed     Abstract available

  139. SAVARESE-BRENNER B, Heugl M, Rath B, Schweizer C, et al
    MUC1 and CD147 Are Promising Markers for the Detection of Circulating Tumor Cells in Small Cell Lung Cancer.
    Anticancer Res. 2022;42:429-439.
    PubMed     Abstract available

  140. HAYASHI K, Suzuki O, Shiomi H, Nakai M, et al
    Stereotactic Ablative Radiotherapy Using CyberKnife for Stage I Non-small-cell Lung Cancer: A Retrospective Analysis.
    Anticancer Res. 2022;42:321-327.
    PubMed     Abstract available

  141. LEE EJ, Park SJ, Lee J, Mun J, et al
    The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study.
    Anticancer Res. 2022;42:363-371.
    PubMed     Abstract available

  142. YASUDA Y, Nagano T, Jimbo N, Kiriu T, et al
    Chloride Intracellular Channel 1 Expression Is Associated With Poor Prognosis of Lung Adenocarcinoma.
    Anticancer Res. 2022;42:271-277.
    PubMed     Abstract available

  143. ASANO Y, Yamamoto N, Hayashi K, Takeuchi A, et al
    Impact of Tumor Growth Speed of Primary Lesions on the Clinical Outcomes of Appendicular Skeletal Metastases.
    Anticancer Res. 2022;42:229-236.
    PubMed     Abstract available

    December 2021
  144. MUTO S, Inomata S, Yamaguchi H, Mine H, et al
    CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLC.
    Anticancer Res. 2021;41:6267-6272.
    PubMed     Abstract available

  145. PUTRI HE, Sritularak B, Chanvorachote P
    Pongamol Inhibits Epithelial to Mesenchymal Transition Through Suppression of FAK/Akt-mTOR Signaling.
    Anticancer Res. 2021;41:6147-6154.
    PubMed     Abstract available

    November 2021
  146. FUJIWARA M, Doi H, Igeta M, Suzuki H, et al
    Radiation Pneumonitis After Volumetric Modulated Arc Therapy for Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:5793-5802.
    PubMed     Abstract available

  147. SHIMODA Y, Yoshida T, Shirasawa M, Mizuno T, et al
    Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2021;41:5739-5747.
    PubMed     Abstract available

  148. SAITO T, Ohnishi K, Ishikawa H, Nakamura M, et al
    Hypofractionated Proton Beam Therapy for cT1-2N0M0 Non-small Cell Lung Cancer Patients With Interstitial Lung Disease.
    Anticancer Res. 2021;41:5635-5642.
    PubMed     Abstract available

  149. SKRICKOVA J, Pesek M, Opalka P, Koubkova L, et al
    Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:5625-5634.
    PubMed     Abstract available

  150. VENCLICEK O, Skrickova J, Brat K, Fischer O, et al
    Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry.
    Anticancer Res. 2021;41:5549-5556.
    PubMed     Abstract available

  151. KURODA H, Masago K, Takahashi Y, Fujita S, et al
    Positive Correlation Between the Number of Circulating Tumor Cells in the Pulmonary Vein and Tumor Spread Through Air Spaces in Resected Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:5499-5505.
    PubMed     Abstract available

  152. NOJIMA Y, Shimizu K, Saisho S, Maeda AI, et al
    Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:5469-5475.
    PubMed     Abstract available

  153. LIAO WC, Huang CW, Hsia TC, Shen YC, et al
    Association of TIMP-2 Rs8179090 Genotypes With Lung Cancer Risk in Taiwan.
    Anticancer Res. 2021;41:5425-5430.
    PubMed     Abstract available

  154. TSOCHANTARIDIS I, Voulgaridou GP, Giatromanolaki A, Koukourakis MI, et al
    Profiling of Aldehyde Dehydrogenase Isoforms in In Vitro Formed Tumorspheres.
    Anticancer Res. 2021;41:5481-5488.
    PubMed     Abstract available

    October 2021
  155. MATSUBARA T, Hirai F, Yamaguchi M, Hamatake M, et al
    Immunonutritional Indices in Non-small-cell Lung Cancer Patients Receiving Adjuvant Platinum-based Chemotherapy.
    Anticancer Res. 2021;41:5157-5163.
    PubMed     Abstract available

  156. MITSUYA S, Tsuruoka K, Kanaoka K, Funamoto T, et al
    Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
    Anticancer Res. 2021;41:5137-5145.
    PubMed     Abstract available

  157. HAMADA K, Yoshimura K, Hirasawa Y, Hosonuma M, et al
    Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy.
    Anticancer Res. 2021;41:4985-4993.
    PubMed     Abstract available

  158. SON KH, Kim MY, Shin JY, Kim JO, et al
    Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations.
    Anticancer Res. 2021;41:4807-4820.
    PubMed     Abstract available

  159. ARAKI K, Yamamuro N, Tomonobu N, Kumon H, et al
    REIC/Dkk-3 Gene Therapy Induces Immunogenic Cell Death in a Mouse Model of Malignant Mesothelioma.
    Anticancer Res. 2021;41:4837-4855.
    PubMed     Abstract available

  160. VODICKA J, Skala M, Sebek J, Treska V, et al
    The Role of Serum Tumor Markers in Follow-up After Surgical Treatment of Malignant Lung Tumors.
    Anticancer Res. 2021;41:5117-5122.
    PubMed     Abstract available

  161. JANSSEN S, Overhoff D, Froelich MF, Schoenberg SO, et al
    Detectability of Lung Nodules in Ultra-low Dose CT.
    Anticancer Res. 2021;41:5053-5058.
    PubMed     Abstract available

  162. KINOSHITA H, Shimozato O, Ishii T, Kamoda H, et al
    The Thioredoxin Reductase Inhibitor Auranofin Suppresses Pulmonary Metastasis of Osteosarcoma, But Not Local Progression.
    Anticancer Res. 2021;41:4947-4955.
    PubMed     Abstract available

    September 2021
  163. SURAPANENI SK, Nottingham E, Mondal A, Patel N, et al
    Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:4215-4228.
    PubMed     Abstract available

  164. KIM SW, DO SI, Na K
    External Validation of ALK and ROS1 Fusions Detected Using an Oncomine Comprehensive Assay.
    Anticancer Res. 2021;41:4609-4617.
    PubMed     Abstract available

  165. YOSHIDA D, Kusunoki T, Takayama Y, Kusano Y, et al
    Comparison of Dose Distribution Between VMAT-SBRT and Scanning Carbon-ion Radiotherapy for Early-stage NSCLC.
    Anticancer Res. 2021;41:4571-4575.
    PubMed     Abstract available

  166. MIRKA H, Ferda J, Krakorova G, Vodicka J, et al
    The Use of CT Pattern in Differentiating Non-invasive, Minimally Invasive and Invasive Variants of Lung Adenocarcinoma.
    Anticancer Res. 2021;41:4479-4482.
    PubMed     Abstract available

  167. SUZUKI S, Yamamoto M, Sanomachi T, Togashi K, et al
    Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin.
    Anticancer Res. 2021;41:4321-4331.
    PubMed     Abstract available

    August 2021
  168. GIATROMANOLAKI A, Anestopoulos I, Panayiotidis MI, Mitrakas A, et al
    Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2021;41:3989-3995.
    PubMed     Abstract available

  169. LAFAUY P, Silapech A, Aksorn N, Sritularak B, et al
    Millettocalyxin B Inhibits Migratory Behavior of Lung Cancer Cells via Integrin alpha5 Suppression.
    Anticancer Res. 2021;41:3843-3849.
    PubMed     Abstract available

  170. OTSUKA T, Ueda K, Furukawa T, Koriyama C, et al
    Significance of Mitochondrial DNA Haplogroup on Epidermal Growth Factor Receptor Mutation in Japanese Patients With Lung Adenocarcinoma.
    Anticancer Res. 2021;41:3997-4004.
    PubMed     Abstract available

  171. YAMANAKA M, Hayashi M, Yamada S, Sonohara F, et al
    A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes.
    Anticancer Res. 2021;41:3933-3940.
    PubMed     Abstract available

    July 2021
  172. SHIONOYA Y, Hirohashi Y, Takahashi H, Hashimoto M, et al
    Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report.
    Anticancer Res. 2021;41:3699-3706.
    PubMed     Abstract available

  173. ZAITSU J, Yamashita Y, Ishikawa A, Saito A, et al
    Systemic Inflammatory Score Predicts Response and Prognosis in Patients With Lung Cancer Treated With Immunotherapy.
    Anticancer Res. 2021;41:3673-3682.
    PubMed     Abstract available

  174. JANG SK, Hong SE, Lee DH, Kim JY, et al
    Inhibition of AKT Enhances the Sensitivity of NSCLC Cells to Metformin.
    Anticancer Res. 2021;41:3481-3487.
    PubMed     Abstract available

    June 2021
  175. LEE GD, Chung B, Song JS, Jang SJ, et al
    The Prognostic Value of Programmed Death-ligand 1 (PD-L1) in Patients who Received Neoadjuvant Chemoradiation Therapy Followed by Surgery for Locally Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:3193-3204.
    PubMed     Abstract available

  176. MOHIUDDIN MD, Kasahara K
    Pemetrexed Disodium Heptahydrate Induces Apoptosis and Cell-cycle Arrest in Non-small-cell Lung Cancer Carrying an EGFR Exon 19 Deletion.
    Anticancer Res. 2021;41:2963-2977.
    PubMed     Abstract available

  177. PUTRI HE, Sritularak B, Chanvorachote P
    DS-1 Inhibits Migration and Invasion of Non-small-cell Lung Cancer Cells Through Suppression of Epithelial to Mesenchymal Transition and Integrin beta1/FAK Signaling.
    Anticancer Res. 2021;41:2913-2923.
    PubMed     Abstract available

  178. KIM SY, Jeong EH, Lee TG, Kim HR, et al
    The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells.
    Anticancer Res. 2021;41:2885-2894.
    PubMed     Abstract available

  179. LIU YC, Hsu FT, Chung JG, Weng MC, et al
    Lenvatinib Induces AKT/NF-kappaB Inactivation, Apoptosis Signal Transduction and Growth Inhibition of Non-small Cell Lung Cancer In Vivo.
    Anticancer Res. 2021;41:2867-2874.
    PubMed     Abstract available

    May 2021
  180. MASUDA T, Wakabayashi YU, Nakashima T, Nishimura Y, et al
    Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone.
    Anticancer Res. 2021;41:2661-2667.
    PubMed     Abstract available

  181. OKIMOTO T, Tsubata Y, Tanino R, Nakao M, et al
    ERCC1 Is a Predictive Biomarker for Non-small Cell Lung Cancer But Is Antibody-dependent.
    Anticancer Res. 2021;41:2653-2660.
    PubMed     Abstract available

  182. SUGIURA H, Miki Y, Iwabuchi E, Saito R, et al
    Estrogen Receptor beta Is Involved in Acquired Resistance to EGFR-tyrosine Kinase Inhibitors in Lung Cancer.
    Anticancer Res. 2021;41:2371-2381.
    PubMed     Abstract available

  183. KREJCI D, Opalka P, Krejci J, Zemanova M, et al
    Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment.
    Anticancer Res. 2021;41:2597-2603.
    PubMed     Abstract available

  184. AOKI K, Nagatani Y, Noma K, Tsugawa T, et al
    Effective Control of Brain Metastases Irrespective of Distance from Isocenter in Single-isocenter Multitarget Stereotactic Radiosurgery.
    Anticancer Res. 2021;41:2575-2581.
    PubMed     Abstract available

  185. HISAKANE K, Seike M, Sugano T, Matsuda K, et al
    PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma.
    Anticancer Res. 2021;41:2501-2509.
    PubMed     Abstract available

  186. GUSHO CA, Blank AT
    What Is the Clinical Impact of Sending Tissue for Histopathology During Surgery for Known, Diffuse Metastatic Disease to Bone?
    Anticancer Res. 2021;41:2473-2476.
    PubMed     Abstract available

  187. SHIROSHITA A, Kurosaki M, Takeshita M, Kataoka Y, et al
    Medical Thoracoscopy, Computed Tomography-guided Biopsy, and Ultrasound-guided Biopsy for Malignant Pleural Mesothelioma: A Systematic Review.
    Anticancer Res. 2021;41:2217-2225.
    PubMed     Abstract available

    April 2021
  188. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Tumor Size and N2 Lymph Node Metastasis Are Significant Risk Factors for Early Recurrence in Completely Resected Centrally Located Primary Lung Cancer Patients.
    Anticancer Res. 2021;41:2165-2169.
    PubMed     Abstract available

  189. TOZUKA T, Yanagitani N, Yoshida H, Manabe R, et al
    Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients.
    Anticancer Res. 2021;41:2093-2100.
    PubMed     Abstract available

  190. SVATON M, Bratova M, Fischer O, Krejci J, et al
    Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study.
    Anticancer Res. 2021;41:2059-2065.
    PubMed     Abstract available

  191. MON MM, Srisomsap C, Chokchaichamnankit D, Watcharatanyatip K, et al
    Serum Proteomic Profiling Reveals Differentially Expressed IGHG3 and A1AG1 as Potential Predictors of Chemotherapeutic Response in Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:1871-1882.
    PubMed     Abstract available

  192. SVATON M, Blazek J, Krakorova G, Pesek M, et al
    Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy.
    Anticancer Res. 2021;41:2053-2058.
    PubMed     Abstract available

  193. SHIBA S, Shibuya K, Okamoto M, Okano N, et al
    Carbon-ion Radiotherapy for Oligometastatic Colorectal Cancer in the Liver or Lung.
    Anticancer Res. 2021;41:1997-2005.
    PubMed     Abstract available

    March 2021
  194. FUKUDA N, Toda K, Ohmoto A, Wang X, et al
    Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib.
    Anticancer Res. 2021;41:1683-1691.
    PubMed     Abstract available

  195. KINOSHITA F, Yamashita T, Oku Y, Kosai K, et al
    Prognostic Impact of Albumin-bilirubin (ALBI) Grade on Non-small Lung Cell Carcinoma: A Propensity-score Matched Analysis.
    Anticancer Res. 2021;41:1621-1628.
    PubMed     Abstract available

  196. NIEDER C, Mannsaker B, Yobuta R
    Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.
    Anticancer Res. 2021;41:1471-1474.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.